Biotech · Private company
Zydus Therapeutics Inc.
Track this companyFree. Adds Zydus Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials186 recruiting or active
Pipeline programs25From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline25
- Saroglitazar Magnesium 1 mgPhase 3 · Primary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 2 mgPhase 3 · Primary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- 50 mg UsnoflastPhase 2 · Amyotrophic Lateral Sclerosis (ALS)ClinicalTrials.gov · fetched Nov 12, 2026
- 75 mg UsnoflastPhase 2 · Amyotrophic Lateral Sclerosis (ALS)ClinicalTrials.gov · fetched Nov 12, 2026
- SaroglitazarPhase 2 · Liver Transplant; ComplicationsClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar magnesium 1 mgPhase 2 · Non-Alcoholic Fatty Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 1 mgPhase 2 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar magnesium 2 mgPhase 2 · Non-Alcoholic Fatty Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar magnesium 2 mgPhase 2 · Primary Biliary CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 2 mgPhase 2 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 2 mgPhase 2 · Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 2mgPhase 2 · Non Alcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar magnesium 4 mgPhase 2 · Primary Biliary CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar magnesium 4 mgPhase 2 · Non-Alcoholic Fatty Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 4 mgPhase 2 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 4 mgPhase 2 · Nonalcoholic Fatty Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 4 mgPhase 2 · Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 4 mg TabletPhase 2 · Non-alcoholic Fatty Liver Disease in Women With PCOSClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 4mgPhase 2 · Non Alcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar magnesiumPhase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar magnesiumPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 1 mgPhase 1 · Cholestatic Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 1 mgPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 2 mgPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- Saroglitazar Magnesium 4 mgPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials18
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyPHASE3 · RECRUITING · started Aug 11, 2026ClinicalTrials.gov NCT07424677 · fetched Nov 12, 2026
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesPHASE3 · RECRUITING · started Mar 24, 2026ClinicalTrials.gov NCT07216235 · fetched Nov 12, 2026
- Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral SclerosisPHASE2 · RECRUITING · started Sep 17, 2025ClinicalTrials.gov NCT07023835 · fetched Nov 12, 2026
- Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver DiseasePHASE1 · RECRUITING · started Aug 5, 2025ClinicalTrials.gov NCT06825559 · fetched Nov 12, 2026
- Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary CholangitisPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 16, 2024ClinicalTrials.gov NCT06427395 · fetched Nov 12, 2026
- Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USPHASE2 · TERMINATED · started Dec 8, 2022ClinicalTrials.gov NCT05211284 · fetched Nov 12, 2026
- Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisPHASE2_PHASE3 · COMPLETED · started Apr 1, 2022ClinicalTrials.gov NCT05133336 · fetched Nov 12, 2026
- Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseasePHASE1 · RECRUITING · started Oct 21, 2021ClinicalTrials.gov NCT05045482 · fetched Nov 12, 2026
- Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisPHASE2 · COMPLETED · started Aug 18, 2021ClinicalTrials.gov NCT05011305 · fetched Nov 12, 2026
- A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal FunctionPHASE1 · COMPLETED · started Jul 27, 2020ClinicalTrials.gov NCT04446507 · fetched Nov 12, 2026
- Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic FunctionPHASE1 · COMPLETED · started Jul 16, 2020ClinicalTrials.gov NCT04469920 · fetched Nov 12, 2026
- Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male SubjectsPHASE1 · COMPLETED · started Sep 20, 2019ClinicalTrials.gov NCT04112446 · fetched Nov 12, 2026
- Saroglitazar Magnesium in the Treatment of Non-Alcoholic SteatohepatitisPHASE2 · COMPLETED · started Jun 12, 2019ClinicalTrials.gov NCT03863574 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)PHASE2 · COMPLETED · started Feb 25, 2019ClinicalTrials.gov NCT03639623 · fetched Nov 12, 2026
- Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)PHASE2 · TERMINATED · started Feb 12, 2019ClinicalTrials.gov NCT03617263 · fetched Nov 12, 2026
- Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary CholangitisPHASE2 · COMPLETED · started Aug 18, 2017ClinicalTrials.gov NCT03112681 · fetched Nov 12, 2026
- Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisPHASE2 · COMPLETED · started Apr 6, 2017ClinicalTrials.gov NCT03061721 · fetched Nov 12, 2026
- Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dLPHASE2 · SUSPENDED · started Apr 6, 2017ClinicalTrials.gov NCT03097107 · fetched Nov 12, 2026